No Data
No Data
HK Stock Announcement: Yankuang Energy plans to cooperate strategically with Highland Resources, which may become the largest shareholder of Highland Resources and acquire control.
Emperor Int'l (00163) plans to sell non-core investment properties in Hong Kong for 1.1547 billion Hong Kong dollars; APEX-BIO (02509) has signed a cooperation agreement with China-US East for the development and potential commercialization of QX005N.
China Traditional Chinese Medicine-B(02509.HK): Collaborating with Sino-America Hua Dong on the development and potential commercialization of QX005N.
On July 21st, Gelonghui announced that Quanxin Biological-B (02509.HK) has signed a cooperation agreement with a wholly-owned subsidiary of huadong medicine (000963.SZ) named China-US huadong on July 19th, 2024. Accordingly, the company grants China-US huadong (i) exclusive joint development rights of the target product in the authorized region and authorized field, (ii) exclusive market promotion selection rights ("selection rights"), and (iii) priority of the transferee of the marketing license holder. The target product QX005N is an anti-IL-4Rα monoclonal antibody (mAb), which has obtained seven items.
Express News | Qyuns Therapeutics - Subscription of Wealth Management Products by Shanghai Pudong Development Bank of RMB60 Mln
Qyuns Therapeutics Invests 260 Million Yuan in Financial Products
Qyuns Therapeutics (HKG:2509) spent an aggregate of 260 million yuan on wealth management products offered by three banks. The subscriptions were made between April 12 and June 4 to maximize the use o
Express News | Qyuns Therapeutics- on May 29. Agreed to Subscribe for Wealth Management Products Offered by Shanghai Pudong Development Bank of RMB100 Mln
Express News | Qyuns Therapeutics - on April 18 Agreed to Subscribe for Wealth Management Products Offered by Bank of Jiangsu With Subscription Amount of RMB50 Mln
No Data